Oslo, 25 May 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced the publication of long-term follow-up data on UV1 in the Journal for ImmunoTherapy of Cancer (JITC). The data show that dynamic UV1 specific immune responses last up to 7.5 years, are associated with longer survival and are enhanced when UV1 is used in combinations with checkpoint inhibitors.

It is important to be able to share this validating data with our research and clinical colleagues through JITC. The data demonstrate highly durable UV1-induced immune responses that are associated with substantially longer overall survival and boosted by checkpoint inhibitors. This is strong support for Ultimovacs broad Phase II program combining UV1 with checkpoint inhibitors across five different cancer indications, said Carlos de Sousa, Chief Executive Officer of Ultimovacs.

The Journal for ImmunoTherapy of Cancer is the peer-reviewed open access journal of the Society for Immunotherapy of Cancer. Ultimovacs paper in JITC reports data from three Phase I/IIa clinical trials on Ultimovacs cancer vaccine lead UV1 in three separate cancer indications malignant melanoma, non-small cell lung cancer (NSCLC) and prostate cancer.

The data demonstrate that UV1 vaccination leads to dynamic immune responses in patients, notably the induction of memory T cells with a cytokine profile involving the production of IFN-gamma and TNF-alpha. Furthermore, the paper demonstrates the development of a UV1-specific immune response associated with longer survival time across the three cancer types.

Adding checkpoint inhibitors boosts the potentially protective UV1 response. UV1-specific immune responses occurred earlier and more frequently in patients with malignant melanoma, where UV1 was combined with the checkpoint inhibitor ipilimumab, than in patients with NSCLC or prostate cancer where no checkpoint inhibitor was involved. Around 91% of patients with malignant melanoma showed a detectable immune response within three months.
Redigert 26.05.2022 kl 07:23